drugset
Drugs / Ad26.ENVA.01
last change May 2016 re-read 3 minutes ago

Ad26.ENVA.01

also known as Ad26-EnvA · rAd26

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Beth Israel Deaconess Medical Center · HIV Vaccine Trials Network · International AIDS Vaccine Initiative · Ragon Institute of MGH, MIT and Harvard

Trials 3

today NCT01215149 · Ph 1 NCT01103687 · Ph 1 NCT00618605 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01215149 Oct 2010 → Dec 2012 HIV infectious disease International AIDS Vaccine Initiative Completed No outcome recorded
Phase 1 NCT01103687 Jul 2010 → Sep 2012 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00618605 Feb 2008 → Jul 2011 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Ad26.ENVA.01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215149 ↗
2

NCT01103687 ↗

NCT00618605 ↗
Known as Ad26-EnvA “All subjects who received the Ad26-EnvA vaccine developed Ad26 NAb titers, EnvA-specific enzyme-linked immunosorbent assays (ELISA) titers, and EnvA-specific enzyme-linked...” PMID 23125444 ↗ Nov 2012
1

“adenovirus serotype 26 with an HIV-1 envelope A insert [Ad26.EnvA]” PMID 26833336 ↗ Feb 2016
Known as rAd26 “Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.” NCT01103687 ↗
Modality Vaccine “Ad26-EnvA vaccine” PMID 23125444 ↗ Nov 2012
Route Intramuscular “delivered intramuscularly (IM)” NCT01103687 ↗